RT Journal Article
SR Electronic
T1 Identification of novel biomarkers for pyridoxine-dependent epilepsy using untargeted metabolomics and infrared ion spectroscopy - biochemical insights and clinical implications
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.22.20248925
DO 10.1101/2021.01.22.20248925
A1 Engelke, Udo F.H.
A1 van Outersterp, Rianne E.
A1 Merx, Jona
A1 van Geenen, Fred A.M.G.
A1 van Rooij, Arno
A1 Berden, Giel
A1 Huigen, Marleen C.D.G.
A1 Kluijtmans, Leo A.J.
A1 Peters, Tessa M.A.
A1 Al-Shekaili, Hilal H.
A1 Leavitt, Blair R.
A1 de Vrieze, Erik
A1 Broekman, Sanne
A1 van Wijk, Erwin
A1 Tseng, Laura A.
A1 Kulkarni, Purva
A1 Rutjes, Floris P.J.T.
A1 Mecinović, Jasmin
A1 Struys, Eduard A.
A1 Jansen, Laura A.
A1 Gospe, Sidney M.
A1 Mercimek-Andrews, Saadet
A1 Hyland, Keith
A1 Willemsen, Michèl A.A.P.
A1 Bok, Levinus A.
A1 van Karnebeek, Clara D.M.
A1 Wevers, Ron A.
A1 Boltje, Thomas J.
A1 Oomens, Jos
A1 Martens, Jonathan
A1 Coene, Karlien L.M.
YR 2021
UL http://medrxiv.org/content/early/2021/01/28/2021.01.22.20248925.abstract
AB Pyridoxine-dependent epilepsy (PDE-ALDH7A1), also known as antiquitin deficiency, is an inborn error of lysine metabolism that presents with refractory epilepsy in newborns. Bi-allelic ALDH7A1 variants lead to deficiency of α-aminoadipic semialdehyde dehydrogenase, resulting in accumulation of piperideine-6-carboxylate (P6C), and secondary deficiency of the important co-factor pyridoxal-5’-phosphate (PLP, active vitamin B6) through its complexation with P6C. Vitamin B6 supplementation resolves epilepsy in patients, but despite this treatment, intellectual disability may occur. Early diagnosis and treatment, preferably based on newborn screening, potentially optimize long-term clinical outcome. However, the currently known diagnostic PDE-ALDH7A1 biomarkers are incompatible with newborn screening procedures. Using a combination of the innovative analytical methods untargeted metabolomics and infrared ion spectroscopy, we have been able to discover novel biomarkers for PDE-ALDH7A1: 2S,6S-and 2S,6R-oxopropylpiperidine-2-carboxylic acid (2-OPP) and 6-oxopiperidine-2-carboxylic acid (6-oxoPIP). We demonstrate the applicability of 2-OPP as a PDE-ALDH7A1 biomarker in newborn screening. Additionally, we show that 2-OPP accumulates in brain tissue of patients and Aldh7a1 knock-out mice, and induces epilepsy-like behavior in a zebrafish model system. We speculate that 2-OPP may contribute to ongoing neurotoxicity, also in treated PDE-ALDH7A1 patients. As 2-OPP formation appears to increase upon ketosis, we emphasize the importance of avoiding catabolism in PDE-ALDH7A1 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was partly funded by a Stimuleringsbeurs from the Society for Inborn Errors of Metabolism for Netherlands and Belgium (ESN), a catalyst grant from United for Metabolic Disease (UMD-CG-2020-004), and a Stofwisselkracht grant under the project name Innovative diagnostics in cerebrospinal fluid of patients with neurometabolic disorders (all to KLMC). Also, parts of this work were financially supported by an Interfacultary Collaboration Grant from Radboud University Nijmegen (to KLMC, RAW, JO and JM). The authors also gratefully acknowledge the Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO), division Natural Sciences, for the support of the FELIX Laboratory (grant numbers VICI 724.011.002, TTW 15769, TKI-LIFT 731.017.419, Rekentijd 2019.062, all to JO). This work was also supported by an ERC-Stg grant (GlycoEdit, 758913) awarded to TJB. This research made use of metabolomics infrastructure that is part of the NWO-funded Netherlands X-omics initiative, project 184.034.019.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The patient material used in this study had been previously collected for routine clinical laboratory diagnostics. All patients (or their guardians) approved of the possible anonimized use of their leftover samples for laboratory method validation purposes, in agreement with institutional and national legislation. The Research Ethics Committee of the Radboud University Medical Centre has approved of this study and has determined that the work was carried out in accordance with the applicable legislation concerning reviewal by an accredited research ethics committee (file number 2021-7296). The use of the autopsy material of the PDE-ALDH7A1 patient was previously approved by the Institutional Review Board of Seattle Childrens Hospital (file number FWA00002443). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data from metabolomics and IRIS experiments has been stored on institutional, backed-up servers and is available upon request.